Clinical trials: Anaplastic Astrocytoma of Brain
Supratentorial Neoplasms, Malignant, Malignant Glioma
HSV G207 Alone or With a Single Radiation Dose in Children With Progressive or Recurrent Supratentorial Brain Tumors
This study is a clinical trial to determine the safety of injecting G207 (a new experimental virus therapy) into a recurrent or progressive brain tumor.
- Conditions
- Supratentorial Neoplasms, Malignant, Malignant Glioma, Glioblastoma, Anaplastic Astrocytoma
- Trial name
- NCT02457845
- Testing
- G207
- Where
- 2 sites in United States
- Volunteers
- 13 people
- Sponsor
- Gregory K. Friedman, MD
Glial Cell Tumors, Malignant Gliomas
Valproic Acid, Radiation, and Bevacizumab in Children With High Grade Gliomas or Diffuse Intrinsic Pontine Glioma
Currently, there are few effective treatments for the following aggressive brain tumors: glioblastoma multiforme, anaplastic astrocytoma, gliomatosis cerebri, gliosarcoma, or brainstem glioma.
- Conditions
- Glial Cell Tumors, Malignant Gliomas, Glioblastoma Multiforme, Anaplastic Astrocytoma
- Trial name
- NCT00879437
- Testing
- Valproic acid, Bevacizumab, Radiation therapy
- Where
- 6 sites in United States
- Volunteers
- 38 people
- Sponsor
- Baylor College of Medicine
Anaplastic Astrocytoma, Anaplastic Oligoastrocytoma
Vaccine Therapy and Sargramostim in Treating Patients With Malignant Glioma
This phase I trial studies the side effects of vaccine therapy when given together with sargramostim in treating patients with malignant glioma.
- Conditions
- Anaplastic Astrocytoma, Anaplastic Oligoastrocytoma, Anaplastic Oligodendroglioma, Giant Cell Glioblastoma
- Trial name
- NCT01250470
- Testing
- Laboratory Biomarker Analysis, Montanide ISA-51/Survivin Peptide Vaccine, Sargramostim
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Roswell Park Cancer Institute
Glioma
Bevacizumab and Carmustine in Treating Patients With Relapsed or Progressive High-Grade Glioma
RATIONALE: Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- NCT00795665
- Testing
- bevacizumab, carmustine
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- University of California, Davis
Brain and Central Nervous System Tumors, Unspecified Adult Solid Tumor, Protocol Specific
Calcitriol Plus Carboplatin in Treating Patients With Advanced Solid Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Calcitriol may help solid tumor cells develop into normal cells.
- Trial name
- NCT00008086
- Testing
- calcitriol, carboplatin
- Where
- United States
- Sponsor
- University of Pittsburgh
Recurrent Childhood Anaplastic Astrocytoma, Recurrent Childhood Brain Stem Glioma
Lapatinib in Treating Young Patients With Recurrent or Refractory Central Nervous System Tumors
This phase I/II trial studies lapatinib to see how well it works in treating young patients with recurrent or refractory central nervous system (CNS) tumors.
- Conditions
- Recurrent Childhood Anaplastic Astrocytoma, Recurrent Childhood Brain Stem Glioma, Recurrent Childhood Ependymoma, Recurrent Childhood Giant Cell Glioblastoma
- Trial name
- NCT00095940
- Testing
- lapatinib ditosylate, therapeutic conventional surgery, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- National Cancer Institute (NCI)
Brain and Central Nervous System Tumors, Psychosocial Effects of Cancer and Its Treatment
Stress Reduction Program in Patients With Malignant Brain Tumors and Their Family Caregivers
RATIONALE: Yoga, meditation, and breathing exercises may help lower stress and improve quality of life in patients with malignant brain tumors and their family caregivers.
- Trial name
- NCT00376818
- Testing
- exercise intervention, educational intervention, physiologic testing
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Case Comprehensive Cancer Center
Brain and Central Nervous System Tumors, Lymphoma
Bortezomib and Temozolomide in Treating Patients With Brain Tumors or Other Solid Tumors That Have Not Responded to Treatment
RATIONALE: Bortezomib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Conditions
- Brain and Central Nervous System Tumors, Lymphoma, Metastatic Cancer, Unspecified Adult Solid Tumor, Protocol Specific
- Trial name
- NCT00544284
- Testing
- bortezomib, temozolomide, pharmacological study
- Where
- 2 sites in United States
- Volunteers
- 25 people
- Sponsor
- City of Hope Medical Center
Brain and Central Nervous System Tumors
Gefitinib in Treating Patients With Recurrent or Progressive CNS Tumors
RATIONALE: Biological therapies such as gefitinib may interfere with the growth of tumor cells and slow the growth of CNS tumors.
- Trial name
- NCT00025675
- Testing
- gefitinib
- Where
- 12 sites in United States
- Volunteers
- 105 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Brain and Central Nervous System Tumors
Phase III Trial of Anaplastic Glioma Without 1p/19q Loss of Heterozygosity (LOH)
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them…
- Trial name
- CATNON (NCT00626990)
- Testing
- temozolomide, DNA methylation analysis, laboratory biomarker analysis
- Where
- 132 sites in United States, Australia and 10 more
- Volunteers
- 751 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Malignant Glioma, Glioblastoma Multiforme
Imaging Study of the Distribution of IL13-PE38QQR Infused Before and After Surgery in Adult Patients With Recurrent Malignant Glioma
The experimental anti-cancer drug IL13-PE38QQR, which is being developed for the treatment of malignant brain tumors, is composed of parts of two proteins: the immune system cytokine IL13 and a toxin from the bacterium…
- Conditions
- Malignant Glioma, Glioblastoma Multiforme, Anaplastic Astrocytoma, Anaplastic Oligodendroglioma
- Trial name
- NCT00064779
- Testing
- IL13-PE38QQR, targeted fusion protein therapy, surgery
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- INSYS Therapeutics Inc
Anaplastic Astrocytoma, Anaplastic Oligoastrocytoma
Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors
This phase I trial studies the side effects and best schedule of vaccine therapy with or without sirolimus in treating patients with cancer-testis antigen (NY-ESO-1) expressing solid tumors.
- Conditions
- Anaplastic Astrocytoma, Anaplastic Oligoastrocytoma, Anaplastic Oligodendroglioma, Estrogen Receptor Negative
- Trial name
- NCT01522820
- Testing
- DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Laboratory Biomarker Analysis, Pharmacological Study
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Roswell Park Cancer Institute
Brain and Central Nervous System Tumors, Lymphoma
Pemetrexed Disodium in Treating Patients With Recurrent Malignant Gliomas, Primary CNS Lymphoma, or Brain Metastases
RATIONALE: Pemetrexed disodium may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying how well pemetrexed disodium works in treating patients with…
- Conditions
- Brain and Central Nervous System Tumors, Lymphoma, Metastatic Cancer
- Trial name
- NCT00276783
- Testing
- pemetrexed
- Where
- 2 sites in United States
- Volunteers
- 31 people
- Sponsor
- Northwestern University
Brain and Central Nervous System Tumors
Immunotoxin Therapy Before and After Surgery in Treating Patients With Recurrent Malignant Glioma
RATIONALE: Immunotoxins can locate tumor cells and kill them without harming normal cells. Immunotoxin therapy may be effective in treating malignant glioma.
- Trial name
- NCT00036972
- Testing
- cintredekin besudotox, adjuvant therapy, conventional surgery
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Glioblastoma, Anaplastic Astrocytoma
A Study of a Retroviral Replicating Vector Combined With a Prodrug Administered to Patients With Recurrent Malignant Glioma
This is a multicenter, open-label, ascending-dose trial of the safety and tolerability of increasing doses of Toca 511, a Retroviral Replicating Vector (RRV), administered to patients with recurrent high grade glioma (rHGG) who…
- Conditions
- Glioblastoma, Anaplastic Astrocytoma, Anaplastic Oligodendroglioma, Anaplastic Oligoastrocytoma
- Trial name
- NCT01156584
- Testing
- Toca 511 vector, Toca FC
- Where
- 10 sites in United States
- Volunteers
- 54 people
- Sponsor
- Tocagen Inc.
High Grade Glioma, Astrocytoma
Study of Olutasidenib and Temozolomide in HGG
The goal of this study is to determine the efficacy of the study drug olutasidenib to treat newly diagnosed pediatric and young adult patients with a high-grade glioma (HGG) harboring an IDH1 mutation.
- Conditions
- High Grade Glioma, Astrocytoma, Astrocytoma, Grade III, Astrocytoma, Grade IV
- Trial name
- NCT06161974
- Testing
- Olutasidenib + TMZ
- Where
- 20 sites in United States, Australia and 5 more
- Volunteers
- 60 people
- Sponsor
- Rigel Pharmaceuticals
Astrocytoma, Oligodendroglioma
Evaluating the Expression Levels of MicroRNA-10b in Patients With Gliomas
MicroRNAs (miRNA) are molecular biomarkers that post-transcriptionally control target genes. Deregulated miRNA expression has been observed in diverse cancers.
- Conditions
- Astrocytoma, Oligodendroglioma, Oligoastrocytoma, Anaplastic Astrocytoma
- Trial name
- NCT01849952
- Where
- 4 sites in United States
- Volunteers
- 94 people
- Sponsor
- Dartmouth-Hitchcock Medical Center
Glioblastoma, Glioblastoma (GBM)
A Phase IB 2 Dose Trial of IRS-1 HSV C134 (IND 17296) Administered Intratumorally in Patients With Recurrent Malignant Glioma
The purpose of this study is to determine how safe and how well-tolerated the experimental study drug, C134 is when administered twice into the brain where the tumor is located. This is a Phase IB 2 dosing study.
- Conditions
- Glioblastoma, Glioblastoma (GBM), Astrocytoma, Astrocytoma, Grade III
- Trial name
- NCT06614855
- Testing
- C134
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- James Markert, MD
Glioblastoma (GBM), DIPG
Prolonged Exposure to Doxorubicin in Patients With Glioblastoma Multiforme and Diffuse Intrinsic Pontine Glioma
The standard therapy of glioblastoma (GBM) consists of gross total resection followed by focal irradiation to the tumor bed with concomitant and adjuvant temozolomide (TMZ).
- Conditions
- Glioblastoma (GBM), DIPG, Brainstem Glioma, Pediatric, Diffuse Spinal Glioma
- Trial name
- NCT02758366
- Testing
- Doxorubicin
- Where
- Italy
- Volunteers
- 21 people
- Sponsor
- Meyer Children's Hospital IRCCS